IDNA - Allogene Therapeutics: Multibagger Potential But Terribly Risky June, 24 2022 10:08 AM iShares Genomics Immunology and Healthcare Allogene's leadership position in allogeneic CAR-T can be rewarding for early investors. However, being a pioneer has its pitfalls. The company has a decent amount of cash. For further details see: Allogene Therapeutics: Multibagger Potential, But Terribly Risky